Ascend’s Post

4P-Pharma reveals today its brand new identity. Founded a decade ago as a biotechnology start-up, 4P-Pharma has now transitioned to a clinical-stage biotech start-up studio focused on developing curative therapies for untreated serious diseases. Revital Rattenbach, the CEO of 4P-Pharma, stated: "The company's new identity marks a new chapter in our evolution to become an integrated pharma company. This transformation injects a fresh wave of energy into our organization, highlighting our audacity, passion for science, and the dynamism of our teams. #4PPharma #transformingscienceintodrugsucceessstories #brandnewidentity

The drug discovery market is booming, with market size surging from $98.01B in 2023 to $111.48B in 2024 (CAGR: 13.7%). Key drivers include advancements in genomics, proteomics, and biopharmaceuticals. Projected to reach $192.2B by 2028 (CAGR: 14.6%), growth is fueled by precision medicine and personalized therapies. Major players ae like Pfizer Inc., Merck., Novartis, Thermo Fisher Scientific Inc. Read more https://lnkd.in/gMBPvC46 #DrugDiscovery #HealthcareInnovation #PrecisionMedicine #Biotech #Pharma #FutureOfMedicine #AI #Genomics #Proteomics #HealthcareExpenditure #tbrc #thebusinessresearchcompany

Highlighting the recent BIO International Convention in San Diego, this Forbes piece touches on an important consideration for any leader in biotech: the notion that "time is your enemy." This industry has no shortage of ambition -- every company I've come across has commendable and inspiring goals to bridge treatment gaps, revolutionize drug delivery, etc. The thing is, we've been having very similar conversations for several years on end, with only a handful of companies demonstrating actual results In that way, I agree that time is our worst enemy. In the words of Bluerock Therapeutics Seth Ettenberg, "Effective prioritization is essential," and learning to focus our efforts in our journey to change medicine. Would love to hear others' thoughts here. #Biotech #DrugDiscovery #NewMedicines

Zhinan Xia, CEO & Founder of @Abimmune Bio, presenting at Day 2 of the 7th Alcor Drug Discovery Platform! Join us as Zhinan introduces their cutting-edge Novel ADC platform, paving the way for transformative therapies. Don't miss out on this opportunity to explore the future of targeted drug delivery! #AlcorDrugDiscovery #ADCPlatform #Innovation #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

🎤 Today, Pierre Eftekhari gave a talk entitled "Optimizing Treatments - The Power, Challenges and Downsides of Patient-Centric Drug Development" at the congress organised by BioPharma Nexus Conference At Inoviem Scientific, we believe it's essential to adopt a patient-centric approach by bringing the clinical reality into drug discovery. That's why we've been working hard for over a decade to build a streamlined platform for patient-centric drug discovery and development. 💪 Here's why we stand out: 👉 𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗜𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻: access to any disease and human material for ex-vivo pharmacology. 👉 𝗘𝗻𝗱-𝘁𝗼-𝗘𝗻𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: covering the entire journey from early discovery to clinical phases. 👉 𝗘𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀: Proprietary technologies that empowering drug development. 🤝 Join us in reshaping the medicine, where innovation and causality go hand in hand. 📧 Reach out to Alessandro Bona - [email protected] #inoviem #drugdevelopment #drugdiscovery #clinicalphases #patientcentric #technology #innovations #healthcarefuture #personalizedmedicine

I’m looking forward to presenting at Biotech X EU on AstraZeneca’s approach in leveraging real-world evidence in our efforts to speed up drug discovery and deliver medicines to patients faster. If you are attending Biotech X EU, please join the session on October 9th for a discussion on where we are currently with the utility of real-world evidence and how the next generation of real-world data will further optimize development decisions.     #BiotechX #OncologyDataScience #RealWorldEvidence #DrugDiscovery

TerrayTherapeuticsAdvances #AIInPharma Terray Therapeutics has secured $120 million in funding to boost its AI-driven small-molecule drug development platform. Led by Bedford Ridge Capital and NVentures, this investment supports Terray's mission to revolutionize drug discovery using its AI model, tNova. The company boasts a vast chemistry dataset, significantly enhancing drug development success rates. Partnerships with Bristol Myers Squibb and Calico Life Sciences highlight Terray's industry influence. #TerrayTherapeutics #AIDrugDevelopment #Biotech #PharmaInnovation #Saasverse What role do you think AI will play in the future of drug development?

Out Now! The June edition of our Pharma Tech Focus Digital Magazine is now live. Almost one year ago, Brazilian president Lula da Silva assembled the first South American summit in nearly a decade to gather the continent’s nations onto a single forum to encourage pharmaceutical trade. In this month’s cover story, we take a look at the progress made since then and identify the main priorities for the public and private pharma sectors in South America. Also in this issue, we continue to follow the opioid crisis in the US, by understanding the nature of the multibillion dollar settlements made by companies implicated in the crisis to several state governments. Now that the legal settlements have been finalised, the next question remains on how to distribute these funds in the best way possible to address the ongoing challenges with those suffering from opioid use disorder. Don’t miss coverage on the burgeoning cell and gene therapy landscape in the US, the challenges with sham patents, and much more.  - https://lnkd.in/g-GSuTCM Also you will find insights from our partners Mimotopes, phasetwo®, Datwyler Healthcare, Xylem, Cytiva and Bea Technologies SpA If you would like information about advertising in future editions please send us a message and a member of the team will get in touch. #pharma #clinicaltrials #opiods #bioprocessing #esg #celltherapy #genetherapy #cellandgene #biotech #biopharma #cdmo #cro

We're thrilled to announce the official launch of the Biospecimen Management Consortium, an alliance of industry leaders committed to driving sample excellence in clinical research. Founding members — including GRAIL, GSK, ILiAD Biotechnologies, LLC, Moderna, Novartis, Roche, Takeda, and Teal Health — will address longstanding inefficiencies and gaps in biospecimen lifecycle management that must be addressed to improve data quality and patient outcomes. Together, the consortium will: - Develop best practices and industry standards - Streamline biospecimen lifecycle operations and data management - Shape the future of regulatory policy We look forward to working with these organizations to transform biosample operations, and we commend them for their unwavering dedication to creating a brighter future in clinical research. To read the full press release, click here: https://lnkd.in/gKxTBBRp #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials

The biopharma industry is evolving rapidly with the emergence of new technologies and methodologies 🔬 MarketsandMarkets™ projects that the global biotech market, driven by groundbreaking advancements and innovative approaches, will reach $465.9 billion in 2024. In our latest article, Roman Bevz, our Head of Business Consulting and Advisory Practice, explores these advancements shaping the sector 🔍 Discover the latest trends in #biopharma, including AI-driven drug discovery, personalized medicine, and other transformative technologies. 🖇️ https://lnkd.in/dQcSqNyE  #Avenga  #AvengaInsights #Biotech #PersonalizedMedicine #TechTrends